Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Silo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSD
Tuesday, November 18, 2025Silo Pharma Inc a diversified developmentalstage biopharmaceutical and cryptocurrency treasury company today announced that it has selected Allucent a global fullservice clinical research organization CRO to support the Companys
ITM Announces FDA Acceptance of New Drug Application (NDA) and PDUFA Date for n.c.a. 177Lu-edotreotide (ITM-11) in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Friday, November 14, 2025ITM Isotope Technologies Munich SE ITM a leading radiopharmaceutical biotech company today announced that the US Food and Drug Administration FDA completed its filing review and accepted the companys New Drug Application
Sarah Cannon Research Institute and Bristol Myers Squibb Expand Strategic Collaboration to Accelerate Patient Enrollment and Broaden Access to Innovative Cancer Research
Thursday, November 13, 2025Sarah Cannon Research Institute SCRI one of the worlds leading oncology research organizations conducting communitybased clinical trials and Bristol Myers Squibb NYSE BMY a leading biopharmaceutical company
Integrated DNA Technologies and Beckman Coulter Life Sciences Partner to Advance Cancer Research Through Automated NGS Workflows
Thursday, November 13, 2025Danaher companies Integrated DNA Technologies IDT a global leader in genomics and Beckman Coulter Life Sciences a global leader in laboratory automation and innovation are forming a strategic partnership to automate IDTs
Revvity to Acquire ACD/Labs to Expand its Signals Software Capabilities
Tuesday, November 11, 2025Revvity Inc today announced it has entered into a definitive agreement to acquire ACDLabs a global provider of scientific software solutions that support analytical characterization and molecular design across pharmaceutical
Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer
Tuesday, November 11, 2025Lyell Immunopharma Inc a latestage clinical company advancing nextgeneration chimeric antigen receptor CAR Tcell therapies for patients with cancer today announced it has strengthened its solid tumor pipeline by acquiring global rights to LYL formerl...
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy
Friday, November 07, 2025Takedatoday announced new interim data from the Phase b openlabel proofof concept study of subcutaneous mezagitamab TAK an antiCD monoclonal antibody with diseasemodifying potential in primary immunoglobulin A IgA nephropathy
U.S. FDA Grants Orphan Drug Designation to Leukogene Therapeutics’ M2T-CD33 (LTI-214) for the Treatment of Acute Myeloid Leukemia
Thursday, November 06, 2025Leukogene Therapeutics Inc LTI a biopharmaceutical company developing nextgeneration immunotherapies for hematologic and other malignancies today announced that the US Food and Drug Administration
PolyActiva and RareSight Form Strategic Collaboration to Develop Breakthrough Treatments for Rare Pediatric Retinal Diseases
Thursday, November 06, 2025PolyActiva a clinicalstage biopharmaceutical company pioneering a novel drug delivery technology to improve outcomes for patients with ocular conditions and RareSight Inc an ophthalmologyfocused life sciences company
Phenomix Sciences Expands Evidence for MyPhenome™ Test Predicting GLP-1 Response and Obesity Risk in Large, Diverse Populations
Wednesday, November 05, 2025Phenomix Sciences Phenomix the first commercial precision obesity medicine biotechnology company today announced results from new research presented at Obesity Week demonstrating the continued clinical utility
